- Home
- KNRX vs BFRI Comparison
KNRX vs BFRI Comparison
Compare KNRX & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNRX | BFRI |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | Singapore | United States |
| Employees | N/A | 94 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 16.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KNRX | BFRI |
|---|---|---|
| Price | $0.38 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | 99.0K | ★ 338.4K |
| Earning Date | 06-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.57 |
| 52 Week High | $3.45 | $1.27 |
Technical Indicators
Market Signals| Indicator | KNRX | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 37.70 | 65.52 |
| Support Level | $0.34 | $0.73 |
| Resistance Level | $0.49 | N/A |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 10.18 | 92.73 |
Price Performance
Historical ComparisonAbout KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.